Key points for selecting patients for heterotopic bicaval therapy in TR and right heart failure

In this discussion, Nadira Hamid and Rishi Puri explore the role of heterotopic valve implantation as an emerging treatment option for severe tricuspid regurgitation. They highlight how bicaval devices, such as the TricValve system, can reduce systemic congestion by addressing caval reflux, particularly in patients who are not suitable for conventional repair or replacement therapies.

Early clinical experience shows rapid improvements in symptoms and quality of life, while ongoing trials aim to establish the long-term benefits of this approach. The key message: heterotopic implantation is becoming an important addition to the therapeutic toolbox for this complex and heterogeneous patient population.

This interview was filmed at EuroPCR 2026: see more videos here.